CytoDyn Inc Banner Image

CytoDyn Inc has reached its limit for free report views

Work for CytoDyn Inc? Upgrade Your Profile and unlock all your annual reports.

CytoDyn Inc

  • Ticker CYDY
    Exchange OTC More
  • Industry Biotechnology More
  • Sector Healthcare More
CytoDyn Inc Logo Image
  • 11-50 Employees
  • Based in Vancouver, Washington
CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has beenMore working diligently to refile its Biologics License Application ("BLA") for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing.
CytoDyn Inc

Most Recent Annual Report

CytoDyn Inc MOST RECENT 2020 Annual Report

Report Locked. CytoDyn Inc has reached its limit for free report views.

Older/Archived Annual Reports